COST-UTILITY ANALYSIS OF DIENOGEST VERSUS GNRH ANALOGUE IN THE TREATMENT OF ENDOMETRIOSIS-ASSOCIATED PELVIC PAIN IN SLOVAKIA

被引：1
|
作者：
Lukac, M. [1 ]
Knight, C. [2 ]
Bielik, J. [3 ]
Tomek, D. [4 ]
Foltan, V [5 ]
Kovac, A. [1 ]
Bojnicky, M. [1 ]
机构：
[1] Slovak Med Univ, Bratislava, Slovakia
[2] RTI Hlth Solut, Sheffield, S Yorkshire, England
[3] Trencin Univ, Trencin, Slovakia
[4] Slovak Soc Pharmacoecon, Bratislava, Slovakia
[5] Comenius Univ, Fac Pharm, Bratislava, Slovakia
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
10.1016/j.jval.2011.02.606
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A109 / A109
页数：1
相关论文
共 50 条
  • [41] Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis
    Petta, CA
    Ferriani, RA
    Abrao, MS
    Hassan, D
    Silva, JCRE
    Podgaec, S
    Bahamondes, L
    HUMAN REPRODUCTION, 2005, 20 (07) : 1993 - 1998
  • [42] A COST-UTILITY ANA LYSIS OF FIRST-LINE TREATMENT IN NEUROPATHIC PAIN: PREGABALIN VERSUS VENLAFAXINE
    Le, D.
    Born, A.
    Brinkerhoff, A.
    Vaidya, V.
    VALUE IN HEALTH, 2016, 19 (03) : A63 - A63
  • [43] COST-MINIMIZATION ANALYSIS OF DIENOGEST VERSUS GONADOTROPHIN-RELEASING HORMONE ANALOGUES OR DYDROGESTERONE FOR ENDOMETRIOSIS TREATMENT IN RUSSIA
    Avxentyeva, M.
    VALUE IN HEALTH, 2013, 16 (07) : A334 - A334
  • [44] Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia
    Alexander H. Miners
    Caroline A. Sabin
    Keith H. Tolley
    Christine A. Lee
    PharmacoEconomics, 2002, 20 : 759 - 774
  • [45] COST-UTILITY ANALYSIS OF INGENOL MEBUTATE VERSUS IMIQUIMOD 5% FOR ACTINIC KERATOSIS TREATMENT IN SPAIN
    Ortega-Joaquin, N.
    Elias, I
    de la Cueva, P.
    Del Pozo, L. J.
    Boada, A.
    Moreno, D.
    Aguilar, M.
    Mosquera, E.
    Mirada, A.
    Gibbons, C.
    Oyaguez, I
    VALUE IN HEALTH, 2015, 18 (07) : A423 - A423
  • [46] COST-UTILITY ANALYSIS OF ORAL SUMATRIPTAN/ NAPROXEN VERSUS ORAL SUMATRIPTAN FOR THE TREATMENT OF ACUTE MIGRAINES
    Lee, J. H.
    Devine, B.
    VALUE IN HEALTH, 2020, 23 : S268 - S268
  • [47] COST-UTILITY ANALYSIS OF INGENOL MEBUTATE VERSUS DICLOFENAC 3% FOR ACTINIC KERATOSIS TREATMENT IN SPAIN
    Elias, I
    Ortega-Joaquin, N.
    Aguilar, M.
    Moreno, D.
    Boada, A.
    Del Pozo, L. J.
    de la Cueva, P.
    Mirada, A.
    Mosquera, E.
    Gibbons, C.
    Oyaguez, I
    VALUE IN HEALTH, 2015, 18 (07) : A423 - A424
  • [48] Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia
    Miners, AH
    Sabin, CA
    Tolley, KH
    Lee, CA
    PHARMACOECONOMICS, 2002, 20 (11) : 759 - 774
  • [49] COST-UTILITY ANALYSIS OF TOCILIZUMAB MONOTHERAPY VERSUS STANDARD OF CARE FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN GREECE
    Athanasakis, K.
    Konstantopoulou, T.
    Tarantilis, F.
    Tsalapati, K.
    Vritzali, E.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2013, 16 (07) : A565 - A565
  • [50] Cost-utility analysis of operative versus non-operative treatment for colorectal liver metastases
    Roberts, K. J.
    Sutton, A. J.
    Prasad, K. R.
    Toogood, G. J.
    Lodge, J. P. A.
    BRITISH JOURNAL OF SURGERY, 2015, 102 (04) : 388 - 398
12345